Objective
Clinical trials of the anti–interleukin‐17A (anti–
IL
‐17A) antibody secukinumab have demonstrated a crucial role of the cytokine
IL
‐17A in the pathogenesis of spondyloarthritis (SpA); however, its cellular source in this condition remains a matter of controversy. Group 3 innate lymphoid cells (
ILC
3s) have been recently identified as potent producers of proinflammatory cytokines, including
IL
‐17A and
IL
‐22, in a number of different tissues. This study was undertaken to characterize the presence and composition of
ILC
s, and investigate whether these cells are an important source of
IL
‐17A, in the synovial tissue (
ST
) of patients with SpA.
Methods
Matched
ST
, synovial fluid, and peripheral blood (
PB
) samples were obtained from SpA patients with actively inflamed knee joints.
ILC
subsets were characterized by flow cytometry. Gene expression analysis at the single‐cell level was performed directly ex vivo and after in vitro activation. An
IL
‐17A enzyme‐linked immunospot assay was used to detect
IL
‐17A–secreting cells.
Results
ILC
s, and particularly
NK
p44+
ILC
3s, were expanded in inflamed arthritic joints. Single‐cell expression analysis demonstrated that
ST ILC
s were clearly distinguishable from
ST
T cells and from their
PB
counterparts. Expression of the Th17 signature transcripts
RORC
,
AHR
, and
IL
23R
was detected in a large proportion of
ST ILC
3s. These cells were capable of inducing expression of
IL
22
and
CSF
2
, but not
IL
17A
, in response to in vitro restimulation.
Conclusion
Our findings demonstrate that absolute and relative numbers of
ILC
3s are enriched in the synovial joints of patients with SpA. However, these cells are not a significant source of
IL
‐17A in this disease.